Literature DB >> 24085647

Metabolic evidence for cerebral neurodegeneration in spinocerebellar ataxia type 1.

Sarah Doss1, Alexander U Brandt, Timm Oberwahrenbrock, Matthias Endres, Friedemann Paul, Jan Leo Rinnenthal.   

Abstract

Autosomal-dominant spinocerebellar ataxia type 1 (SCA1) is an adult-onset progressive disorder with well-characterized neurodegeneration in the cerebellum and brainstem. The objective of this study is to evaluate neurochemical changes associated with neurodegeneration in cerebral tissue in SCA1 patients compared to age- and gender-matched healthy controls. Nine patients with genetically proven SCA1 and nine gender- and age-matched healthy controls were prospectively recruited from the ataxia clinic and received clinical examination. A 1.5 T single-voxel brain proton MR spectroscopy was performed for total N-acetyl aspartate (tNAA) in cerebellum, parietofrontal lobe white matter, sensory cortex, and visual cortex. In the patients, tNAA was severely decreased in the cerebellar voxel; however, in the voxels positioned in sensory cortex, parietofrontal lobe white matter and visual cortex tNAA was reduced in comparison to controls. In addition to the profoundly affected cerebellum, we also found evidence for cerebral neurodegeneration in parietal lobe white matter, sensory cortex, and visual cortex in SCA1 patients illustrating a multisystem neurodegenerative character of the disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24085647     DOI: 10.1007/s12311-013-0527-2

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  31 in total

1.  Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1.

Authors:  M Mascalchi; M Tosetti; R Plasmati; M C Bianchi; C Tessa; F Salvi; M Frontali; F Valzania; C Bartolozzi; C A Tassinari
Journal:  Ann Neurol       Date:  1998-02       Impact factor: 10.422

2.  1H NMR chemical shift selective (CHESS) imaging.

Authors:  A Haase; J Frahm; W Hänicke; D Matthaei
Journal:  Phys Med Biol       Date:  1985-04       Impact factor: 3.609

3.  Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy.

Authors:  Gülin Oz; Isabelle Iltis; Diane Hutter; William Thomas; Khalaf O Bushara; Christopher M Gomez
Journal:  Cerebellum       Date:  2011-06       Impact factor: 3.847

4.  Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6.

Authors:  Kathrin Reetz; Ana S Costa; Shahram Mirzazade; Anna Lehmann; Agnes Juzek; Maria Rakowicz; Romana Boguslawska; Ludger Schöls; Christoph Linnemann; Caterina Mariotti; Marina Grisoli; Alexandra Dürr; Bart P van de Warrenburg; Dagmar Timmann; Massimo Pandolfo; Peter Bauer; Heike Jacobi; Till-Karsten Hauser; Thomas Klockgether; Jörg B Schulz
Journal:  Brain       Date:  2013-02-18       Impact factor: 13.501

5.  Brain white matter damage in SCA1 and SCA2. An in vivo study using voxel-based morphometry, histogram analysis of mean diffusivity and tract-based spatial statistics.

Authors:  Riccardo Della Nave; Andrea Ginestroni; Carlo Tessa; Elena Salvatore; Domenico De Grandis; Rosaria Plasmati; Fabrizio Salvi; Giuseppe De Michele; Maria Teresa Dotti; Silvia Piacentini; Mario Mascalchi
Journal:  Neuroimage       Date:  2008-07-11       Impact factor: 6.556

6.  Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6.

Authors:  Ina Klinke; Martina Minnerop; Tanja Schmitz-Hübsch; Marc Hendriks; Thomas Klockgether; Ullrich Wüllner; Christoph Helmstaedter
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

7.  Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status.

Authors:  Gülin Oz; Diane Hutter; Ivan Tkác; H Brent Clark; Myron D Gross; Hong Jiang; Lynn E Eberly; Khalaf O Bushara; Christopher M Gomez
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

8.  Brain structural damage in spinocerebellar ataxia type 2. A voxel-based morphometry study.

Authors:  Riccardo Della Nave; Andrea Ginestroni; Carlo Tessa; Mirco Cosottini; Marco Giannelli; Elena Salvatore; Ferdinando Sartucci; Giuseppe De Michele; Maria Teresa Dotti; Silvia Piacentini; Mario Mascalchi
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites.

Authors:  J Frahm; H Bruhn; M L Gyngell; K D Merboldt; W Hänicke; R Sauter
Journal:  Magn Reson Med       Date:  1989-07       Impact factor: 4.668

10.  Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1.

Authors:  Sarah Stricker; Timm Oberwahrenbrock; Hanna Zimmermann; Jan Schroeter; Matthias Endres; Alexander U Brandt; Friedemann Paul
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

View more
  4 in total

1.  Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency.

Authors:  Sarah Doss; Jan Leo Rinnenthal; Tanja Schmitz-Hübsch; Alexander U Brandt; Sebastian Papazoglou; Silke Lux; Stephan Maul; Jens Würfel; Matthias Endres; Thomas Klockgether; Martina Minnerop; Friedemann Paul
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 2.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

Review 3.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

4.  Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1.

Authors:  Frederike Cosima Oertel; Oliver Zeitz; Maria Rönnefarth; Charlotte Bereuter; Seyedamirhosein Motamedi; Hanna G Zimmermann; Joseph Kuchling; Anne Sophie Grosch; Sarah Doss; Andrew Browne; Friedemann Paul; Tanja Schmitz-Hübsch; Alexander U Brandt
Journal:  Mov Disord Clin Pract       Date:  2020-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.